Showing results (241-250 of 285) with videos related to

Sort By:
Pageof 29
BMC Genomics|December 19, 2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancerKaren A Ryall, Jihye Kim, Peter J Klauck, et al.
Molecular Cancer Therapeutics|March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerJohn J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Anti-Cancer Drugs|July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer modelsAnna Capasso, Todd M Pitts, Peter J Klauck, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|February 4, 2016
Preventing the Progression of Intestinal Failure-Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipidIvan R Diamond, Robert C Grant, Paul B Pencharz, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2022
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignanciesWen Wee Ma, Jenny J Li, Nilofer S Azad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer modelsJennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, et al.
Frontiers in Oncology|July 30, 2025
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer CenterAhmed Alsafar, Sama L Kareem, Bradley R Corr, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Frontiers in Oncology|April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal AdenocarcinomaSarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Pageof 29